The link between psoriatic arthritis comorbidity index and clinical characteristics in patients with psoriatic arthritis (Eng)
Article Sidebar
Main Article Content
Abstract
Objectives: Psoriatic arthritis comorbidity index (PsACI) was developed specifically to assess comorbidity in psoriatic arthritis (PsA) patients. This study aimed to investigate the association between PsaCI and clinical characteristics in patients with PsA
Methods: This is a cross sectional study including PsA patients who visited the Rheumatology Clinic at Hospital Raja Permaisuri Bainun. Their clinical characteristics and comorbidities were recorded.
Results: This study population consisted of 172 patients with PsA. There were 77 males (44.8%) and 95 females (55.2%). Hypertension (59.9%) was the most common comorbidity, followed by dyslipidemia (46.5%) and diabetes mellitus (36.1%). The PsACI score was significantly associated with age and obesity (p<0.001). Further analysis revealed that both the age of onset for psoriasis and the age of onset for PsA exceeding 45 years were positively correlated with higher PsACI scores. PsACI did not correlate with the multiple domains of PsA, the site of psoriasis or treatment regimen given.
Conclusions: The findings underscore the critical importance of managing comorbid conditions in PsA patients, especially among those with an earlier age of psoriasis onset, older patients with PsA, and those with obesity. The results showed the overall comorbidity burden may be influenced more by patient-specific factors rather than disease-specific factors. Further research is needed to better understand the interplay between comorbidities and PsA.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
(ใส่ข้อความเดียวกันกับ ก๊อปปี้ไลน์ก็ได้)ดูตัวอย่างได้ที่หน้าบทความ---บทความนี้ตีพิมพ์เป็นลิขสิทธื์ของใคร...
References
Bilal J, Malik SU, Riaz IB, Kurtzman DJB Psoriasis and psoriatic spectrum disease: a primer for the primary care physician. Am J Med 2018; 131:1146–1154
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376(10):957–70.
Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res 2017;69:67-74
Kotsis K, Voulgari PV, Tsifetaki N, Machado MO, Carvalho AF, Creed F, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res 2012;64:1593-601
Kathuria P, Gordon KB, Silverberg JI. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol 2017;76:1045-53
Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review. Ann Rheum Dis 2013; 72: 211-6.
Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res 2017;69:51-7.
Mok CC, Ko GT, Ho LY, et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011; 63(2): 195-202
El Miedany Y, El Gaafary M, Youssef S, et al. Psoriatic Arthritis comorbidity index: development and validation of a new specific tool for classifying prognostic comorbidity in psoriasis and psoriatic arthritis patients. Rheumatol Orthop Med, 2017; 2: 1-7.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665–73.
Shah K, Paris M, Mellars L, Changolkar A, Mease PJ. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open.2017 ;3:e000588. doi:10.1136/rmdopen-2017-000588
Pina Vegas L, Sbidian E, Penso L, Claudepierre P. Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database. Rheumatology (Oxford). (2021) 60:1243– 51.
Husted JA, Thavaneswaran A, Chandran V, et al. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol 2013; 40: 1349–1356.
Jafri K, Bartels CM, Shin D, et al. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res 2017; 69: 51–57
Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 2011; 63: 1729–1735
Garshick MK, Kimball AB. Psoriasis and the life cycle of persistent life effects. Dermatol Clin 2015;33:25-39.
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxi- dative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33- 39.
Ludwig RJ. Platelet activation in psoriasis: A possible link to skin inflammation. J Invest Dermatol 2001; 117: 766.
Puig L, Strohal R, Husni ME, Tsai TF, Noppakun N, Szumski A, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate to severe psoriasis and psoriatic arthritis. J Dermatolog Treat 2015;26:7 15.
Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 2014;41:1357 65.
di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013;65:141 7.
Koliaki, C., Liatis, S. & Kokkinos, A. Obesity and cardiovascular disease: Revisiting an old relationship. Metabolism 2019 ;92:98–107
Gossec L, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen et al. Ann Rheum Dis 2024;0:1–14. doi:10.1136/ard-2024-225531
Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-1847
Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8(6): R186.
Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69(2): 325-331.
Y. El Miedany, M. El Gaafary, S. Youssef, Sami Bahlas, M. Hegaz. Psoriatic arthritis comorbidity index: development and validation of a new specific tool for classifying prognostic comorbidity in psoriasis and psoriatic arthritis patients. Rheumatol Orthop Med.2017;2:1-7
Aslam F, Khan NA. Tools for the Assessment of Comorbidity Burden in Rheumatoid Arthritis. Front Med (Lausanne). 2018;16(5):39. 20
England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the Rheumatic Disease Comorbidity Index: RDCI Validation. Arthritis Care Res. 2015;67(6):865–72.
Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2020;51(1):219–229.
Gialouri CG, Fragoulis GE. Disease activity indices in psoriatic arthritis: current and evolving concepts. Clin Rheumatol 2021; 40: 4427–4435